New EMA Fees Could Shake Up Pharma Submission Strategies

 
• By Vibha Sharma

Companies that delay their drug application submissions to the European Medicines Agency by more than 60 days will face an additional fees of €4,200 per delay under a new regulation effective from 2025.

Hour glass and calendar concept for time slipping away for important appointment date, schedule and deadline
Companies That Do Not Stick to Their Filing Plans Risk Incurring Additional Costs (Shutterstock)

More from EMA

More from Geography